

60. Gershberg, H., Hulse, M., and Javier, Z. Hypertriglyceridemia during treatment with estrogen and oral contraceptives: An alteration in hepatic function? *Obstet Gynec* 31:186, 1968.
61. Gershberg, H., Javier, Z., and Hulse, M. Glucose tolerance in women receiving an ovulatory suppressant. *Diabetes* 13:378, 1964.
62. Gershberg, H., Zorrilla, E., Hernandez, A., and Hulse, M. Effects of medroxyprogesterone acetate on serum insulin and growth hormone levels in diabetes and potential diabetics. *Obstet Gynec* 33:383, 1969.
- 62a. Glick, I. D. Mood and behavioral changes associated with the use of the oral contraceptive agents. A review of the literature. *Psychopharmacologia (Berlin)* 10:363, 1967.
63. Goh, K. Personal communication.
64. Gold, E. M., Carvajal, J., Rudnick, P. A., and Gerszi, K. E. Insulin production in overt (maturity-onset) diabetes: Absence of hyperinsulinemia despite hyperglycemia induced by contraceptive steroids. Salhanick, H. A., Ed. Conference on metabolic effects of gonadal hormones and contraceptive steroids. December 1-5, 1968.
65. Goldsmith, N. F., and Baumberger, J. P. Mineral changes after norethynodrel. *Lancet* 2:567, 1967.
66. Goldsmith, N. F., and Goldsmith, J. R. Epidemiological aspects of magnesium and calcium metabolism. *Arch Environ Health (Chicago)* 12:607, 1966.
- 66a. Goldzieher, J. W., Bacerra, C., Gual, C., Livingston, Jr., N. B., Maqueo, M., Moses, L. E., and Tietze, C. A new contraceptive. *Amer J Obstet Gynec* 90:404, 1964.
67. Goldzieher, J. W., Rice-Wray, E., Shultz-Contreras, M., and Aranda-Rosella, C. A. Fertility following termination of contraception with norethindrone. *Amer J Obstet Gynec* 84:1474, 1962.
68. Goodrich, S. M., and Wood, E. J. Peripheral venous distensibility and velocity of venous blood flow during pregnancy or during oral contraceptive therapy. *Amer J Obstet Gynec* 90:740, 1964.
69. Goolden, A. W. G., Gartside, J. M., and Sanderson, C. Thyroid status in pregnancy and in women taking oral contraceptives. *Lancet* 1:12, 1967.
- 69a. Grant, E. C., and Pryse-Davies, J. Effect of oral contraceptive on depressive mood changes and on endometrial monoamine oxidase and phosphatases. *Brit Med J* 3:777, 1968.
70. Gregoire, A. T., and Ledger, W. J. The glycogen content of human ectocervical tissues of females receiving steroid contraceptive therapy. *Fertil Steril* 20:91, 1969.
71. Gregoire, A. T., Rankin, J., Johnson, W. D., Fakoff, A. E., and Adams, A. Alpha-amylase content in cervical mucus of females receiving sequential, nonsequential or no contraceptive therapy. *Fertil Steril* 18:836, 1967.
72. Hagler, S., Schultz, A., Hankin, H., and Kunstadter, R. H. Fetal effects of steroid therapy during pregnancy. *Amer J Dis Child* 106:96, 1963.
73. Harkavy, M., and Javitt, N. B. Effect of ethynyl estradiol on hepatic excretory function of the rat. Salhanick, H. A., Ed. Conference on metabolic effects of gonadal hormones and contraceptive steroids. December 1-5, 1968.
- 73a. Hazzard, W. R., Spiger, M. J., Bagdade, J. D. and Bierman, E. L. Studies on the mechanism of increased plasma triglyceride levels induced by oral contraceptives. *New Eng J Med* 280:471, 1969.
74. Hellman, L. M. Safety of oral contraceptives. *Texas Rep Biol Med* 25:318, 1967.
75. Helmer, O. M., and Griffith, R. S. The effect of the administration of estrogens on the renin-substrate (hypertensinogen) content of rat plasma. *Endocrinology* 51:421, 1952.
76. Hilliard, J., Croxatto, H. B. Hayward, J. N., and Sawyer, C. H. Norethindrone blockade of LD release to intrapituitary infusion of hypothalamic extract. *Endocrinology* 79:411, 1966.
77. Hollander, C. S., Garcia, A. M., Sturgis, S. H., and Slenkow, H. A. Effects of an ovulatory suppressant of the serum PBI and red cell uptake of radioactive triiodothyronine. *New Eng J Med* 269:501, 1963.
78. Horowitz, B. J., Solomkin, M., and Edelstein, S. W. The over-suppression syndrome. *Obstet Gynec* 31:387, 1968.